# IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

> **NCT01979393** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 58 (actual)

## Conditions studied

- Uterine Sarcoma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01979393
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-02
- **Primary completion:** 2022-05-18
- **Final completion:** 2024-01-15
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01979393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01979393, "IRCI Gynae Sarcomas, High Grade Uterine Sarcoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01979393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*